Previous close | 2,880.00 |
Open | 2,790.00 |
Bid | 2,719.00 x 100 |
Ask | 0.00 x 2500 |
Day's range | 2,719.00 - 2,790.00 |
52-week range | 2,250.80 - 3,070.53 |
Volume | |
Avg. volume | 534 |
Market cap | 4.863T |
Beta (5Y monthly) | 0.56 |
PE ratio (TTM) | 47.39 |
EPS (TTM) | 57.88 |
Earnings date | 25 July 2024 - 29 July 2024 |
Forward dividend & yield | 103.69 (3.78%) |
Ex-dividend date | 12 Apr 2024 |
1y target est | N/A |
Pharmaceutical giant AbbVie Inc. (ABBV) shares came under pressure as the market closed on Friday, following the disappointing first quarter sales performance of the company's arthritis drug, Humira. The company forecast that Humira's sales could slow further in the face of heightened competition. Yahoo Finance's health reporter Anjalee Khemlani breaks down the details, providing insight into the rise of biosimilars in the market. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith
Discover how AbbVie Inc (ABBV) exceeded forecasts with robust revenue growth and strategic expansions in its latest quarterly earnings.